RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...

Boston and New York are gearing up to host two of the most impressive stars in global athletics. Jess Hull and Georgia Bell, ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million ...

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of ...

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...

Heartland Dental, the nation's leading dental support organization, is pleased to announce the appointment of Sherianne James ...

I-Mab halts CD73 program to focus on givastomig, General Proximity emerges with $16M for undruggable proteins, PBS Biotech raises $17M, Citius explores sale ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius ...

Olympic champion Masai Russell recently shared her 'vision board' achievements as she reflected on her 2024 season.

Denileukin diftitox is under clinical development by Citius Oncology and currently in Pre-Registration for Mycosis Fungoides.